drugset
drugset / Trial / NCT05112159

Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

NCT05112159 ↗

Phase 1 Completed 76 enrolled Nanjing Immunophage Biotech Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.

Timeline

Start
2021-09-27
Primary completion
2022-07-25
Completion
2022-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject IPG1094 Unknown 100 mg Oral
Subject IPG1094 Unknown 200 mg Oral
Subject IPG1094 Unknown 300 mg Oral
Subject IPG1094 Unknown 600 mg Oral
Subject IPG1094 Unknown 900 mg Oral
Subject IPG1094 Unknown 1200 mg Oral

Indications

No indication recorded.